Tx3 announces the release of the next generation Tx3VERA platform, supporting integration with Jira.
Blue Bell PA— May 13, 2019—Tx3 announces the release of the next generation Tx3VERA platform, supporting integration with Jira. Tx3VERA provides a quality and compliance platform enabling the review and approval of electronic records across a number of different Dev/Ops tools from a single user interface. The availability of the Tx3VERA adapter for Jira provides the controls to enable compliance with 21 CFR Part 11 for Life Science companies using Jira.
“We are very excited with our expansion of VERA to DevOps with VERA for Jira. VERA for Jira’s seamless integration and configurability provides an easy to use approval mechanism, visibility into the approval process and FDA compliant electronic records and signatures.” said Henry Farris, CTO at Tx3 Services, LLC.
Tx3 VERA with MicroFocus ALM has been deployed at numerous Pharmaceutical, Biotech, and Medical Device companies. Tx3 continues to expand the Tx3 VERA platform to provide a common review and approval user experience across industry leading Dev/Ops tools. The platform will provide a system of record for electronic signatures including end to end life cycle traceability, supporting the leading test automation technologies. Our clients will be enabled to leverage the benefits of Data Driven Validation in a Waterfall, Agile or a Hybrid environment.
With more than 40,000 companies using Jira, it was a logical target for the first Tx3 VERA adapter release. Tx3 continues to evaluate the best in class tools as it builds out the Tx3VERA platform.
Founded in 2014, Tx3 is a software development compliance company that provides workflow controls and electronic signature capabilities for a wide range of application lifecycle tools and methodologies. These solutions help life sciences companies achieve regulatory compliance in their GxP systems.
For more information contact:
Contact Name: Eric Toburen
For more information on Product:
+1 (877) 225-6677
email us here
Source: EIN Presswire